ESSA Pharma Inc
Change company Symbol lookup
Select an option...
EPIX ESSA Pharma Inc
EVAX Evaxion Biotech A/S
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp
ADERW 26 Capital Acquisition Equity Warrant Exp 31 Dec 2027 *W EXP 12/31/2027
CMI Cummins Inc
Go

Health Care : Biotechnology | Small Cap Growth
Based in Canada
Company profile

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer. The Company's lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The Company is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

Closing Price
$2.90
Day's Change
-0.05 (-1.69%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.98
Day's Low
2.86
Volume
(Light)
Volume:
134,324

10-day average volume:
274,089
134,324

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.